Tolerated doses in zebrafish of cytochalasins and jasplakinolide for comparison with tolerated doses in mice in the evaluation of pre-clinical activity of microfilament-directed agents in tumor model systems in vivo

In Vivo

Volumn 28, Issue 6, 2014, Pages 1021-1032

  Trendowski, Matthew ^a   Wong, Victoria ^a   Wellington, Karie ^a   Hatfield, Suzanne ^a   Fondy, Thomas P ^a  

^a SYRACUSE UNIVERSITY   (United States)

Author keywords

21,22 dihydro Cytochalasin B; Chemotherapy; Cytochalasin B; Cytochalasin C; Cytochalasin D; Cytochalasins; Glutathione; Jasplakinolide; Microfilament directed agents; Toxicity; Zebrafish

Indexed keywords

CYTOCHALASIN A; CYTOCHALASIN B; CYTOCHALASIN C; CYTOCHALASIN D; CYTOCHALASIN DERIVATIVE; DIHYDROCYTOCHALASIN B; GLUTATHIONE; JASPAMIDE; ANTINEOPLASTIC AGENT; CYTOCHALASIN; DEPSIPEPTIDE;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; DRUG EXPOSURE; DRUG TOLERABILITY; FOLLOW UP; IN VIVO STUDY; LD 50; LETHALITY; MICROFILAMENT; MOUSE; NONHUMAN; OXIDATION; ZEBRA FISH; ACTIN FILAMENT; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG SCREENING; NEOPLASMS; PATHOLOGY; TOXICITY TESTING;

ACTIN CYTOSKELETON; ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHALASINS; DEPSIPEPTIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; MICE; MOLECULAR STRUCTURE; NEOPLASMS; TOXICITY TESTS, ACUTE; ZEBRAFISH;

EID: 84918515076     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Weinberg RA: The biology of cancer, 2nd Edition. Garland Science 2013.
2. Van Goietsenoven G, Mathieu V, Andolfi A, Cimmino A, Lefranc F, Kiss R and Evidente A: In vitro growth inhibitory effects of cytochalasins and derivatives in cancer cells. Planta Med 77(7): 711-717, 2011.
3. Trendowski M, Yu G, Wong V, Acquafondata C, Christen T and Fondy TP: The real deal: using cytochalasin B in sonodynamic therapy to preferentially damage leukemia cells. Anticancer Res 34: 2195-2202, 2014.
4. Kolber MA and Hill P: Vincristine potentiates cytochalasin Binduced DNA fragmentation in vitro . Cancer Chemother Pharmacol 30(4): 286-290, 1992.
5. Bogyo D, Fondy SR, Finster L, Fondy C, Patil S and Fondy TP: Cytochalasin-B-induced immunosuppression of murine allogeneic anti-tumor response and the effect of recombinant human interleukin-2. Cancer Immunol Immunother 32(6): 400-405, 1991.
6. Medina D, Oborn CJ and Asch BB: Distinction between preneopastic and neoplastic mammary cell populations in vitro by cytochalasin B-induced multinucleation. Cancer Res 40(2): 329-333, 1980.
7. Matesic DF, Villio KN, Folse SL, Garcia EL, Cutler SJ and Cutler HG: Inhibition of cytokinesis and akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells. Cancer Chemother Pharmacol 57(6): 741-754, 2006.
8. Tikoo A, Cutler H, Lo SH, Chen LB and Maruta H: Treatment of Ras-induced cancers by the F-actin cappers tensin and chaetoglobosin K, in combination with the caspase-1 inhibitor N1445. Cancer J Sci Am 5(5): 293-300, 1999.
9. Knudsen PB, Hanna B, Ohl S, Sellner L, Zenz T, Döhner H, Stilgenbauer S, Larsen TO, Lichter P and Seiffert M: Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton. Leukemia 28(6): 1289-1298, 2014.
10. Konishi H, Kikuchi S, Ochiai T, Ikoma H, Kubota T, Ichikawa D, Fujiwara H, Okamoto K, Sakakura C, Sonoyama T, Kokuba Y, Sasaki H, Matsui T and Otsuji E: Latrunculin a has a strong anticancer effect in a peritoneal dissemination model of human gastric cancer in mice. Anticancer Res 29 (6): 2091-2097, 2009.
11. Sayed KA, Khanfar MA, Shallal HM, Muralidharan A, Awate B, Youssef DT, Liu Y, Zhou YD, Nagle DG and Shah G: Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells. J Nat Prod 71(3): 396-402, 2008.
12. Stingl J, Andersen RJ and Emerman JT: In vitro screening of crude extracts and pure metabolites obtained from marine invertebrates for the treatment of breast cancer Cancer Chemother Pharmacol 30(5): 401-406, 1992.
13. Senderowicz AM, Kaur G, Sainz E, Laing C, Inman WD, Rodríguez J, Crews P, Malspeis L, Grever MR and Sausville EA: Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton. J Natl Cancer Inst 87(1): 46-51, 1995.
14. Bousquet PF, Paulsen LA, Fondy C, Lipski KM, Loucy KJ and Fondy TP: Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma. Cancer Res 50(5): 1431-1439, 1990.
15. Scherlach K, Boettger D, Remme N and Hertweck C: The chemistry and biology of cytochalasans. Nat Prod Rep 27 (6): 869-886, 2010.
16. Huang FY, Mei WL, Li YN, Tan GH, Dai HF, Guo JL, Wang H, Huang YH, Zhao HG, Zhou SL, Li L and Lin YY: The antitumour activities induced by pegylated liposomal cytochalasin D in murine models. Eur J Cancer 48 (14): 2260-2269, 2012.
17. Huang FY, Li YN, Mei WL, Dai HF, Zhou P and Tan GH: Cytochalasin D, a tropical fungal metabolite, inhibits CT26 tumor growth and angiogenesis. Asian Pac J Trop Med 5 (3): 169-174, 2012.
18. Stracke ML, Soroush M, Liotta LA and Schiffmann E: Cytoskeletal agents inhibit motility and adherence of human tumor cells. Kidney Int 43(1): 151-157, 1993.
19. Malecki JM, Bentke A, Ostrowska B and Laidler P: Cytochalasin D, LY294002 and olomoucine synergize in promoting death of melanoma cells through activation of caspase-3 and apoptosis. Melanoma Res 20(1): 52-58, 2010.
20. Walling EA, Krafft GA and Ware BR: Actin assembly activity of cytochalasins and cytochalasin analogs assayed using fluorescence photobleaching recovery. Arch Biochem Biophys 264(1): 321-332, 1988.
21. Singh J and Hood RD: Effects of protein deficiency on the teratogenicity of cytochalasins in mice. Teratology 35(1): 87-93, 1987.
22. Terada Y, Simerly C and Schatten G: Microfilament stabilization by jasplakinolide arrests oocyte maturation, cortical granule exocytosis, sperm incorporation cone resorption, and cell-cycle progression, but not DNA replication, during fertilization in mice. Mol Reprod Dev 56(1): 89-98, 2000.
23. 2+ entry. FEBS Lett 586(1): 89-95, 2012.
24. Chabner BA and Longo DL: Cancer chemotherapy and biotherapy: Principles and practice, 5th Edition. Lipincott Williams & Wilkins 2011.
25. Scott VR, Boehme R and Matthews TR: New class of antifungal agents: jasplakinolide, a cyclodepsipeptide from the marine sponge, Jaspis species. Antimicrob Agents Chemother 32(8): 1154-1157, 1988.
26. Makioka A, Kumagai M, Ohtomo H, Kobayashi S and Takeuchi T: Effect of jasplakinolide on the growth, encystation, and actin cytoskeleton of Entamoeba histolytica and Entamoeba invadens. J Parasitol 87(2): 399-405, 2001.
27. Holzinger A: Jasplakinolide. An actin-specific reagent that promotes actin polymerization. Methods Mol Biol 161: 109-120, 2001.
28. Holzinger A and Meindl U: Jasplakinolide, a novel actin targeting peptide, inhibits cell growth and induces actin filament polymerization in the green alga Micrasterias. Cell Motil Cytoskeleton 38(4): 365-372, 1997.
29. Wing DA, Powers B and Hickok D: U.S. Food and Drug Administration drug approval: slow advances in obstetric care in the United States. Obstet Gynecol 115(4): 825-833, 2010.
30. Johnson JR, Ning YM, Farrell A, Justice R, Keegan P and Pazdur R: Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst 103(8): 636-644, 2011.
31. Feitsma H and Cuppen E: Zebrafish as a cancer model: Mol Cancer Res 6(5): 685-694, 2008.
32. Epperly MW, Bahary N, Quader M, Dewald V and Greenberger JS: The zebrafish - Danio rerio - is a useful model for measuring the effects of small-molecule mitigators of late effects of ionizing irradiation. In Vivo 201226(6): 889-897, 2012.
33. Liu S and Leach SD: Zebrafish models for cancer: Annu Rev Pathol 6: 71-93, 2011.
34. White R, Rose K and Zon L: Zebrafish cancer: the state of the art and the path forward. Nat Rev Cancer 13(9): 624-636, 2013.
35. Lagunoff D: The reaction of cytochalasin A with sulfhydryl groups. Biochem Biophys Res Commun 73(3): 727-732, 1976.
36. Lipski KM, McQuiggan JD, Loucy KJ and Fondy TP: Cytochalasin B: preparation, analysis in tissue extracts, and pharmacokinetics after intraperitoneal bolus administration in mice. Anal Biochem 161(2): 332-340, 1987.
37. Austin WL, Wind M and Brown KS: Differences in the toxicity and teratogenicity of cytochalasins D and E in various mouse strains. Teratology 25 (1): 11-18, 1982.
38. Takeuchi H, Ara G, Sausville EA and Teicher B: Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma. Cancer Chemother Pharmacol 42 (6): 491-496, 1998.
39. Martineau SN, Andreassen PR and Margolis RL: Delay of HeLa cell cleavage into interphase using dihydrocytochalasin B: retention of a postmitotic spindle and telophase disc correlates with synchronous cleavage recovery. J Cell Biol 131(1): 191-205, 1995.
40. Shilagardi K, Li S, Luo F, Marikar F, Duan R, Jin P, Kim JH, Murnen K and Chen EH: Actin-propelled invasive membrane protrusions promote fusogenic protein engagement during cellcell fusion. Science 340(6130): 359-363, 2013.
41. Kolber MA and Hill P: Vincristine potentiates cytochalasin Binduced DNA fragmentation in vitro . Cancer Chemother Pharmacol 30 (4): 286-290, 1992.
42. Armstrong JS, Steinauer KK, Hornung B, Irish JM, Lecane P, Birrell GW, Peehl DM and Knox SJ: Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ 9(3): 252-263, 2002.
43. Davis Jr. W, Ronai Z, and Tew K: Cellular Thiols and Reactive Oxygen Species in Drug-Induced Apoptosis. J Pharmacol Exp Ther 296(1): 1-6, 2001.
44. Moran LK, Gutteridge JM and Quinlan GJ: Thiols in cellular redox signalling and control. Curr Med Chem 8(7): 763-772, 2001.
45. Deneke SM: Thiol-based antioxidants: Curr Top Cell Regul 36: 151-180, 2000.
46. Ketterer B, Coles B and Meyer DJ: The role of glutathione in detoxication. Environ Health Perspect 49: 59-69, 1983.